Answers are grounded in this paper and cite their sources.
Predicting major histocompatibility complex class II (MHC-II)–restricted epitopes is challenging; however, AlphaFold (AF) may provide a structure-based pan-prediction solution. In this study, we have established the new tool AF-prediction (AF-pred) with a clear standard for quantitative prediction results of MHC-II–restricted epitopes. We validated AF-pred using MHC-II molecules from humans, pigs, cattle, and bats, with this validation including large-scale in silico analyses with known immunopeptidome datasets, as well as in vitro binding assays and crystallographic characterization of newly predicted epitopes. When compared to sequence-based tools heavily trained with the human immunopeptidome, AF-pred demonstrates advantages in the prediction of cross-species MHC-II binding patterns. Using unreported bat MHC-II structures, we analyzed the prediction capability, logic, and limitations of AF-pred. In addition, we explored the impact of the AF algorithm iterations on the prediction of MHC-II–restricted epitopes. These results demonstrate that AF-pred is capable of cross-species prediction of MHC-II–restricted epitopes, which is conducive to the development of novel T-cell epitope vaccines and the advancement of the “One Health” initiative. • AlphaFold prediction (AF-pred) can predict major histocompatibility complex (MHC) class II-restricted epitopes. • The structure-based tool AF-pred exhibits distinct advantages in cross-species prediction. • AF-pred supporting T-cell epitope vaccine development and "One Health" implementation.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: